Stocks · Healthcare · Medical - Devices
Cytek Biosciences, Inc. CTKB
$6.09 +3.75% Close, Oct 5, 2026 · NASDAQ · Market cap $758.1M
Strong trend
Next earnings report: Nov 4, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin narrowed to -21.6% from -13.7% a year earlier.
- Over the past year the stock returned +66.8%, ahead of the S&P 500 by 51.1 percentage points.
- Revenue over the last four quarters was $206.7M, up 5.4% from a year earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 6, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 41%
- FCF growth (TTM, YoY)Bottom 5%
- Revenue growth, 3-year CAGRBottom 42%
- Revenue growth accelerationTop 29%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 43%
- Gross marginBottom 37%
- Operating marginBottom 42%
- Accruals (lower is better)Top 19%
- Interest coverBottom 25%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 45%
- Free-cash-flow yieldTop 40%
- EBITDA / enterprise valueTop 49%
- Sales / enterprise valueTop 43%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 44%
- 6-month returnTop 30%
- 1-year return vs S&P 500Top 23%
- Distance from 52-week highTop 4%
- Trend checklist (0–4)Top 10%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 5%
- Consecutive EPS beatsBottom 49%
- Share of analysts rating BuyBottom 25%
- Upside to consensus price targetBottom 4%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 28%
- Maximum drawdown, 3 yearsBottom 43%
- Beta vs S&P 500 (lower is better)Bottom 48%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 3.6% | 5.4% | ↑ |
| Gross margin | 54.4% | 53.2% | ↓ |
| Operating margin | -13.7% | -21.6% | ↓ |
| FCF margin | 5.6% | -5.8% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 5.4% | 3.6% | ↑ | Bottom 41% |
| Gross margin | 53.2% | 54.4% | ↓ | Bottom 37% |
| Operating margin | -21.6% | -13.7% | ↓ | Bottom 42% |
| Net margin | -39.0% | -3.3% | ↓ | — |
| Free-cash-flow margin | -5.8% | 5.6% | ↓ | — |
| Return on invested capital | -11.9% | — | Top 43% | |
| Revenue growth, 3-year CAGR | 7.1% | — | Bottom 42% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -16.7%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 10.3%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -14.9 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -25.3×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.09%
- Shareholder yield
- -0.09%
- Share count change, 1 year
- +2.0%
- Share count change, 3-year CAGR
- -1.6%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 5, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 1
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- -100.0%
- Average 2-day reaction, last 8
- +0.4%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $4.88
- Target vs current price
- -19.9%
- Analysts with a rating
- 5
- Share rating Buy or Strong Buy
- 60%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 5, 2026 | +46.4% | -2.3% | +10.7% | +7.9% | — |
| May 7, 2026 | -50.0% | -0.4% | -25.5% | -12.3% | -12.8% |
| Feb 26, 2026 | -1600.0% | +0.7% | +0.9% | +5.3% | -9.4% |
| Nov 5, 2025 | +66.7% | +2.6% | +22.5% | +37.1% | +32.0% |
| Aug 6, 2025 | -100.0% | +0.3% | +3.9% | +1.5% | +3.4% |
| May 8, 2025 | -125.0% | +1.6% | -26.8% | -10.5% | +2.9% |
| Feb 27, 2025 | +40.0% | -3.8% | -10.6% | -18.4% | -51.0% |
| Nov 5, 2024 | +200.0% | +4.6% | +37.5% | +29.0% | +3.7% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | -$0.05 | -$0.09 | +46.4% | $48.1M |
| May 7, 2026 | -$0.12 | -$0.08 | -50.0% | $44.1M |
| Feb 26, 2026 | -$0.34 | -$0.02 | -1600.0% | $62.1M |
| Nov 5, 2025 | -$0.01 | -$0.03 | +66.7% | $52.3M |
| Aug 6, 2025 | -$0.04 | -$0.02 | -100.0% | $45.6M |
| May 8, 2025 | -$0.09 | -$0.04 | -125.0% | $41.5M |
| Feb 27, 2025 | $0.07 | $0.05 | +40.0% | $57.5M |
| Nov 5, 2024 | $0.01 | -$0.01 | +200.0% | $51.5M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 3.44× | — | — | Top 43% |
| Free-cash-flow yield | -1.59% | — | — | Top 40% |
| Earnings yield | -10.23% | — | — | Bottom 45% |
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 17
- Days above the 200-day average
- 17
- 50-day average slope (20 days)
- +7.0%
- 200-day average slope (20 days)
- +0.2%
- Distance from 50-day average
- +25.0%
- Distance from 200-day average
- +31.8%
- RSI (14)
- 75.0
- Relative volume
- 1.24×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 44.4%
- Volatility vs own 5-year history
- 8th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.15
- Correlation with S&P 500
- 0.25
- Current drawdown from 1-year high
- +0.0%
- Maximum drawdown, 3 years
- -74.6%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Sep 15, 2021 | May 23, 2025 | -91.3% | 926 days | Not yet recovered |
| Aug 10, 2021 | Aug 30, 2021 | -24.9% | 14 days | 11 days (Sep 15, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $758.1M
- EPS, diluted (TTM)
- -$0.62
- Revenue (TTM)
- $206.7M
- 52-week range
- $3.31 – $6.18
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $128.0M | $164.0M | $193.0M | $200.5M | $201.5M |
| Gross profit | $79.1M | $101.0M | $109.4M | $111.1M | $104.5M |
| Operating income | $9.2M | -$1.8M | -$27.8M | -$20.5M | -$40.4M |
| Net income | $3.0M | $2.6M | -$12.1M | -$6.0M | -$66.5M |
| EPS (diluted) | $0.03 | $0.02 | -$0.09 | -$0.05 | -$0.52 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $51.5M | $57.5M | $41.5M | $45.6M | $52.3M | $62.1M | $44.1M | $48.1M |
| Net income | $941,000 | $9.6M | -$11.4M | -$5.6M | -$5.5M | -$44.1M | -$18.9M | -$12.2M |
| EPS (diluted) | $0.01 | $0.07 | -$0.09 | -$0.04 | -$0.04 | -$0.34 | -$0.15 | -$0.09 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $4.6M | -$12.2M | $5.3M | $25.4M | -$4.7M |
| Capital expenditure | -$4.4M | -$9.9M | -$4.8M | -$3.5M | -$4.1M |
| Free cash flow | $266,000 | -$22.1M | $454,000 | $21.9M | -$8.8M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $215.7M | $2.8M | -$44.2M | -$21.6M | -$13.6M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $262.0M
- Total assets
- $446.9M
- Total liabilities
- $125.0M
- Total debt
- $26.5M
- Net debt
- -$47.4M
- Shareholders’ equity
- $322.0M
As of Jun 30, 2026 (filed Aug 5, 2026).
Short interest
- Shares sold short
- 5,242,079
- Days to cover
- 5.74
- Change vs previous report
- +6.3%
FINRA short interest, settlement date Sep 15, 2026.